Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure N.V. reports company news on its gene therapy pipeline, regulatory interactions, clinical data, operating results, and capital structure. The company develops genetic medicines for severe diseases, with disclosed programs including AMT-130 for Huntington’s disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, ALS programs, and an approved gene therapy for hemophilia B.
Recurring updates cover FDA and MHRA discussions, clinical-trial observations, exploratory efficacy and safety data, quarterly and annual financial results, debt financing arrangements, corporate presentations, and governance or shareholder matters tied to its Nasdaq-listed public-company status.
uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 32 newly hired employees as an incentive for their employment. As per Nasdaq Listing Rule 5635(c)(4), the grants, approved on April 29, 2022, include 84,900 restricted stock units and options to purchase 119,000 ordinary shares at an exercise price of $14.94 per share, reflecting the share's closing price on the grant date. The options will vest over four years, while the RSUs will vest over three years, contingent on the employees' continued service.
uniQure N.V. announces the FDA's acceptance for priority review of the Biologics License Application (BLA) for etranacogene dezaparvovec, a gene therapy aimed at treating hemophilia B. If approved, this therapy would be the first of its kind for patients suffering from this condition. The treatment has shown a 64% reduction in bleeding rates post-infusion in the pivotal HOPE-B trial. With CSL Behring as its commercialization partner, uniQure aims to provide a transformative solution for individuals with hemophilia B.
uniQure N.V. (NASDAQ: QURE) announced granting equity awards to 32 new employees to incentivize their employment. This decision, approved on April 29, 2022, follows Nasdaq Listing Rule 5635(c)(4). The grants consist of 84,900 restricted stock units (RSUs) and options to purchase 119,000 ordinary shares at an exercise price of $14.94 per share, which is the closing price on the Grant Date. The options will vest over four years; RSUs will vest over three years, subject to continued employment.
uniQure N.V. (NASDAQ: QURE) announced six data presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting from May 16-19, 2022, in Washington, D.C. Highlights include an oral presentation on alpha-synuclein lowering in Parkinson's models and several poster sessions covering advancements in AAV gene therapies. Dr. Ricardo Dolmetsch emphasized the innovative potential of the linQURE® cargo platform in silencing mutant C9orf72 in ALS preclinical models. The event underscores uniQure's commitment to advancing gene therapies for severe medical conditions.
uniQure N.V. (QURE) reported Q1 2022 financial results, with revenues of $1.8 million, up from $0.5 million in Q1 2021, driven by collaboration revenue from CSL Behring. The company received $55 million in milestone payments related to the regulatory progress of etranacogene dezaparvovec for hemophilia B, which was validated by the EMA for accelerated assessment. R&D expenses rose to $45 million, while SG&A expenses decreased to $11 million. The net loss was $46.7 million, or $1.00 per share. Cash and equivalents stood at $524.9 million, projected to fund operations into H1 2025.
CSL Behring's Marketing Authorization Application (MAA) for etranacogene dezaparvovec has been accepted for accelerated assessment by the EMA, potentially making it the first gene therapy for hemophilia B. Supported by the phase 3 HOPE-B study, which showed a 64% reduction in annual bleeds after a single infusion, this breakthrough therapy aims to significantly improve patients' lives. Etranacogene dezaparvovec addresses the underlying genetic cause of hemophilia B, offering hope for a transformative treatment option in the EU and EEA.
uniQure N.V. (NASDAQ: QURE) announced the completion of enrollment for the first two cohorts in its Phase I/II clinical trial of AMT-130, targeting early-stage Huntington's disease. A total of 26 patients were enrolled across two cohorts, with initial results expected in Q2. This trial aims to evaluate the safety and efficacy of AMT-130, a gene therapy designed to reduce harmful protein levels associated with the disease. A third cohort is planned to refine the administration procedure. The trial advances uniQure's commitment to innovative gene therapies addressing critical medical needs.
uniQure N.V. (QURE) reported a significant revenue increase to $524 million for 2021 from $37.5 million in 2020, driven primarily by a $462.4 million license revenue from its CSL Behring agreement. The company ended 2021 with $556 million in cash, sufficient to fund operations into 2025. Positive clinical data from the HOPE-B trial demonstrated the efficacy of etranacogene dezaparvovec for hemophilia B, with a 64% reduction in annualized bleeding rate. Ongoing studies for Huntington’s Disease and new therapies for refractory temporal lobe epilepsy and Fabry disease are advancing, maintaining a strong pipeline.
uniQure announced the dosing of the first two patients in its European Phase Ib/II clinical trial of AMT-130, a gene therapy for Huntington’s disease. The trial will include 15 patients across Poland, the UK, and Germany. Dr. Ricardo Dolmetsch reported that patient enrollment is expected to finish by year-end, with preliminary data anticipated in Q2 2022. The innovative AMT-130 aims to silence the huntingtin gene using a proprietary AAV5 vector, marking a significant step in gene therapy advancements for neurodegenerative disorders.
CSL Behring released positive long-term results from the Phase 3 HOPE-B trial of etranacogene dezaparvovec (EtranaDez), a gene therapy for hemophilia B. The study showed a stable increase in mean Factor IX (FIX) activity, reaching 36.9 IU/dL at 18 months post-infusion. Participants experienced a 64% reduction in annual bleeding rates and 98% discontinued prophylactic treatment. The therapy was generally well-tolerated, though one unrelated death occurred. This data reinforces the potential of EtranaDez to transform hemophilia B management and may accelerate regulatory reviews in the U.S. and Europe.